News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

FDA Warning Hurts Hikma Pharmaceuticals Generics Margins


5/17/2012 8:05:36 AM

Hikma Pharmaceuticals Plc said it expects profitability in its generics business to be hurt by continuing price competition and steps it has taken to comply with a warning letter from U.S. regulators. In February, the company received a warning letter from the U.S. Food and Drugs Administration (FDA) about operations at its Eatontown oral dosage facility in New Jersey. Hikma said it was enhancing its processes to address the regulator's observations but the actions would slow sales in the first half.

Read at Reuters


comments powered by Disqus
Reuters
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES